KR101988255B1 - Fraction of fermented product using omeginuruk having antioxidative, antihypertensive and whitening activity and method of preparing the same - Google Patents
Fraction of fermented product using omeginuruk having antioxidative, antihypertensive and whitening activity and method of preparing the same Download PDFInfo
- Publication number
- KR101988255B1 KR101988255B1 KR1020170085293A KR20170085293A KR101988255B1 KR 101988255 B1 KR101988255 B1 KR 101988255B1 KR 1020170085293 A KR1020170085293 A KR 1020170085293A KR 20170085293 A KR20170085293 A KR 20170085293A KR 101988255 B1 KR101988255 B1 KR 101988255B1
- Authority
- KR
- South Korea
- Prior art keywords
- formic acid
- fermented product
- fraction
- product
- activity
- Prior art date
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 37
- 230000002087 whitening effect Effects 0.000 title claims abstract description 36
- 230000003276 anti-hypertensive effect Effects 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000000855 fermentation Methods 0.000 claims abstract description 41
- 230000004151 fermentation Effects 0.000 claims abstract description 41
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 26
- 238000004440 column chromatography Methods 0.000 claims abstract description 19
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 74
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 51
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 37
- 235000019253 formic acid Nutrition 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 23
- 239000012153 distilled water Substances 0.000 claims description 21
- 239000012046 mixed solvent Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 14
- -1 acetone Nitrile Chemical class 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 5
- 239000002537 cosmetic Substances 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 235000012149 noodles Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 81
- 235000006708 antioxidants Nutrition 0.000 description 23
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 18
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 235000013312 flour Nutrition 0.000 description 9
- 241000209094 Oryza Species 0.000 description 8
- 235000007164 Oryza sativa Nutrition 0.000 description 8
- 235000009566 rice Nutrition 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 6
- 108060008724 Tyrosinase Proteins 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000021438 curry Nutrition 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 235000019992 sake Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 240000006439 Aspergillus oryzae Species 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000306281 Mucor ambiguus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000000231 Sesamum indicum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-M D-tartrate(1-) Chemical compound OC(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-M 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108091023242 Internal transcribed spacer Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000196877 Xylaria arbuscula Species 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GNHOJBNSNUXZQA-UHFFFAOYSA-J potassium aluminium sulfate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GNHOJBNSNUXZQA-UHFFFAOYSA-J 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000899 pressurised-fluid extraction Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/18—Fractionation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 항산화, 항고혈압 또는 미백활성을 갖는 오메기곡 발효 분획물의 제조방법 및 제조된 오메기곡 발효 분획물의 용도에 관한 것이다. 구체적으로 본 발명에 따른 오메기곡 발효 분획물의 제조방법은 (a) 오메기곡을 이용하여 발효물을 제조하는 단계; (b) 상기 (a)단계의 발효물로부터 1kDa 이하의 분자량을 갖는 발효물을 수득하는 단계; 및 (c) 상기 (b) 단계에서 수득한 발효물을 컬럼 크로마토그래피를 수행하여 분획화하는 단계를 포함하며, 상기 방법으로 제조된 오메기곡 발효 분획물은 우수한 항산화, 항고혈압 또는 미백활성을 갖는 특징이 있어 건강 기능성 식품, 화장품 및 의약품의 용도로 사용될 수 있는 효과가 있다.The present invention relates to a process for producing the Omegi-Kogaku fermentation fraction having antioxidant, antihypertensive or whitening activity, and the use of the Omegi-Kogaku fermentation fraction thus produced. Specifically, the process for producing the fermentation broth of Omegi Oil according to the present invention comprises the steps of: (a) preparing a fermentation product using omega noodles; (b) obtaining a fermentation product having a molecular weight of 1 kDa or less from the fermentation product of step (a); And (c) fractionating the fermented product obtained in the step (b) by column chromatography. The fermented fraction of Omegigi produced by the above method has excellent antioxidant, antihypertensive or whitening activity Can be used for health functional foods, cosmetics and medicines.
Description
본 발명은 항산화, 항고혈압 및 미백활성을 갖는 오메기곡 발효물, 상기 발효물의 분획물 및 이의 제조방법에 관한 것이다.The present invention relates to a fermented product of Omegi, having antioxidant, antihypertensive and whitening activity, fractions of the fermented product and a process for producing the same.
오메기곡이란 오메기술에 사용하는 누룩으로 제주 지방에서는 토속주인 좁쌀약주와 오메기술의 제조에 사용된다. 제주에서는 쌀이 귀하여 보리와 조를 주식으로 삼았기에 보리를 이용한 오메기술을 즐겨 빚어오고 있다.Omegi is a yeast that is used in omega technology. It is used in Jeju province for the manufacture of omega and japanese rice wine. In Jeju, rice has been used as a stock and barley and rice as stocks.
한편, 누룩은 자연 상태에서 곰팡이, 효모, 세균류 등 많은 종류의 미생물이 번식되어 만들어져 왔으며, 누룩의 종류에 따라 미생물의 분포가 상이하고 따라서 미생물에 의한 효소활성, 효모 함유량 및 알코올 발효력 등이 달라지므로 누룩에 따라 제조되는 제품은 각기 다른 기능을 나타낼 수 있으며, 누룩이 큰 영향을 미치는 것으로 보고되고 있다.On the other hand, yeast has been produced by breeding many kinds of microorganisms such as fungi, yeast, and fungi in a natural state. Since the distribution of microorganisms differs depending on the type of yeast, enzyme activity, yeast content and alcohol fermentation ability by microorganisms are changed Products manufactured according to yeast can exhibit different functions, and yeast has been reported to have a large effect.
따라서 이러한 누룩을 이용한 발효제품은 체내 유용한 생리활성을 가지고 있어 누룩을 활용한 각종 기능성 제품의 개발이 활발히 진행되고 있다.Therefore, fermented products using such yeast have useful physiological activities in the body, and various functional products utilizing yeast are being actively developed.
일반적으로 발효는 미생물이 자신이 가지고 있는 효소를 이용하여 유기물을 분해시키는 과정을 일컫는 것으로, 발효를 통해 수득한 산물은 인체 유용하게 작용된다. 이에 최근에는 각종 발효제품의 개발이 이어지고 있고 특히 현대화 시대는 건강을 더욱 중시 여기는 사회 풍조가 깊어짐에 따라 체내 안정성이 높으면서도 기능성이 우수한 제품에 대한 소비자의 관심이 증대되고 있다.Generally, fermentation refers to a process in which a microorganism decomposes an organic material using an enzyme of its own, and the product obtained through fermentation is useful for the human body. Recently, the development of various fermented products has been continuing. Especially, in the era of modernization, as the social trend that emphasizes health is more deepened, consumers are increasingly interested in products having high stability and high functionality.
이에 본 발명자들은 오메기곡을 이용하여 발효물로부터 항산화, 항고혈압 및 미백 활성이 우수한 특정 분획물을 제조하는 공정을 확립하였고, 이의 활성을 확인하였다.Thus, the present inventors have established a process for producing a specific fraction having excellent antioxidant, antihypertensive and whitening activity from fermented products using Omega-Goku, and confirmed its activity.
따라서 본 발명의 목적은 항산화, 항고혈압 또는 미백활성을 갖는 오메기곡 발효 분획물의 제조방법을 제공하는 것이다.Accordingly, an object of the present invention is to provide a process for producing the Omega-3 fermentation fraction having antioxidant, antihypertensive or whitening activity.
본 발명의 다른 목적은 오메기곡 발효물 또는 오메기곡 발효 분획물을 유효성분으로 포함하는 항산화, 항고혈압 또는 미백용 식품 조성물을 제공하는 것이다.It is another object of the present invention to provide an antioxidant, antihypertensive or whitening food composition containing the Omega-3 fermented product or the Omega-3 fermented product as an active ingredient.
본 발명의 또 다른 목적은 오메기곡 발효물 또는 오메기곡 발효 분획물을 유효성분으로 포함하는 항산화 또는 피부미백용 화장료 조성물을 제공하는 것이다.It is still another object of the present invention to provide a cosmetic composition for antioxidant or skin whitening comprising an Omega-3 fermented product or an Omega-3 fermented fraction as an active ingredient.
상기와 같은 본 발명의 목적을 달성하기 위해서, 본 발명은 (a) 오메기곡을 이용하여 발효물을 제조하는 단계; (b) 상기 (a)단계의 발효물로부터 1kDa 이하의 분자량을 갖는 발효물을 수득하는 단계; 및 (c) 상기 (b) 단계에서 수득한 발효물을 컬럼 크로마토그래피를 수행하여 분획화하는 단계를 포함하는, 항산화, 항고혈압 또는 미백활성을 갖는 오메기곡 발효 분획물의 제조방법을 제공한다.In order to accomplish the object of the present invention, the present invention provides a method for producing a fermented product, comprising the steps of: (a) (b) obtaining a fermentation product having a molecular weight of 1 kDa or less from the fermentation product of step (a); And (c) fractionating the fermentation product obtained in the step (b) by column chromatography to produce a fermentation broth of Omegi Valley having antioxidant, antihypertensive or whitening activity.
본 발명의 일실시예에 있어서, 상기 (a)단계의 발효물은 오메기곡을 이용하여 20 ~ 45℃ 온도에서 7일~21일 동안 발효시켜 제조한 발효물일 수 있다.In one embodiment of the present invention, the fermented product of step (a) may be a fermented product produced by fermenting the fermented product at 20 to 45 ° C. for 7 days to 21 days using Omega Curve.
본 발명의 일실시예에 있어서, 상기 (c) 단계의 분획화는 0.1% 포름산이 함유된 증류수 및 0.1% 포름산이 함유된 아세토니트릴의 혼합용매를 이용하여 농도구배로 분획화한 것일 수 있다.In one embodiment of the present invention, the fractionation in step (c) may be performed by fractionating a concentration gradient using a mixed solvent of distilled water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid.
본 발명의 일실시예에 있어서, 0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 11.8~13.6 : 88.2~86.4로 하여 수득한 분획물은 항고혈압 활성 및 미백 활성을 갖는 것일 수 있다. In one embodiment of the present invention, the fraction obtained by setting the mixed solvent concentration gradient of distilled water containing 0.1% formic acid: acetonitrile containing 0.1% formic acid to 11.8 to 13.6: 88.2 to 86.4 exhibited antihypertensive activity and whitening activity Lt; / RTI >
본 발명의 일실시예에 있어서, 0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 16.4~18.0 : 83.6~82.0으로 하여 수득한 분획물은 항산화 활성을 갖는 것일 수 있다.In one embodiment of the present invention, the fraction obtained by adjusting the mixed solvent concentration gradient of distilled water containing 0.1% formic acid: acetonitrile containing 0.1% formic acid to 16.4 to 18.0: 83.6 to 82.0 may be one having antioxidative activity have.
또한, 본 발명은 오메기곡 발효물 또는 오메기곡 발효 분획물을 유효성분으로 포함하는 항산화, 항고혈압 또는 미백용 식품 조성물을 제공한다.Further, the present invention provides an antioxidant, antihypertensive or whitening food composition comprising the Omega-3 fermented product or the Omega-3 fermented fraction as an active ingredient.
본 발명의 일실시예에 있어서, 상기 분획물은 1kDa 이하의 분자량을 갖는 오메기곡 발효물을 컬럼 크로마토그래피를 수행하여 수득한 것으로, 0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 11.8~13.6 : 88.2~86.4로 하여 수득한 분획물은 항고혈압 활성을 갖는 것일 수 있다.In one embodiment of the present invention, the fraction is obtained by performing column chromatography on Omegigok's fermented product having a molecular weight of 1 kDa or less, and is obtained by dissolving 0.1% formic acid-distilled water: acetonitrile containing 0.1% formic acid The fraction obtained by setting the mixed solvent concentration gradient to 11.8 to 13.6: 88.2 to 86.4 may be one having antihypertensive activity.
본 발명의 일실시예에 있어서, 상기 분획물은 1kDa 이하의 분자량을 갖는 오메기곡 발효물을 컬럼 크로마토그래피를 수행하여 수득한 것으로, 0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 16.4~18.0 : 83.6~82.0으로 하여 수득한 분획물은 항산화 활성을 갖는 것일 수 있다.In one embodiment of the present invention, the fraction is obtained by performing column chromatography on Omegigok's fermented product having a molecular weight of 1 kDa or less, and is obtained by dissolving 0.1% formic acid-distilled water: acetonitrile containing 0.1% formic acid The fraction obtained by setting the mixed solvent concentration gradient at 16.4 to 18.0: 83.6 to 82.0 may be one having antioxidative activity.
또한 본 발명은, 오메기곡 발효물 또는 오메기곡 발효 분획물을 유효성분으로 포함하는 항산화 또는 피부미백용 화장료 조성물을 제공한다.The present invention also provides a cosmetic composition for antioxidant or skin whitening comprising an Omega-3 fermented product or an Omega-3 fermented fraction as an active ingredient.
본 발명의 일실시예에 있어서, 상기 오메기곡 발효 분획물은 1kDa 이하의 분자량을 갖는 오메기곡 발효물을 컬럼 크로마토그래피를 수행하여 수득한 것으로, 0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 11.8~13.6 : 88.2~86.4로 하여 수득한 분획물은 미백 활성을 갖는 것일 수 있다. In one embodiment of the present invention, the Omega-type fermentation fraction is obtained by performing column chromatography on a Omegi type fermented product having a molecular weight of 1 kDa or less, and is characterized in that 0.1% formic acid-containing distilled water: 0.1% formic acid- The fraction obtained by setting the mixed solvent concentration gradient of acetonitrile to 11.8 to 13.6: 88.2 to 86.4 may be one having a whitening activity.
본 발명의 일실시예에 있어서, 상기 분획물은 1kDa 이하의 분자량을 갖는 오메기곡 발효물을 컬럼 크로마토그래피를 수행하여 수득한 것으로, 0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 16.4~18.0 : 83.6~82.0으로 하여 수득한 분획물은 항산화 활성을 갖는 것일 수 있다.In one embodiment of the present invention, the fraction is obtained by performing column chromatography on Omegigok's fermented product having a molecular weight of 1 kDa or less, and is obtained by dissolving 0.1% formic acid-distilled water: acetonitrile containing 0.1% formic acid The fraction obtained by setting the mixed solvent concentration gradient at 16.4 to 18.0: 83.6 to 82.0 may be one having antioxidative activity.
본 발명에 따른 오메기곡 발효 분획물의 제조방법은 (a) 오메기곡을 이용하여 발효물을 제조하는 단계; (b) 상기 (a)단계의 발효물로부터 1kDa 이하의 분자량을 갖는 발효물을 수득하는 단계; 및 (c) 상기 (b) 단계에서 수득한 발효물을 컬럼 크로마토그래피를 수행하여 분획화하는 단계를 포함하며, 상기 방법으로 제조된 오메기곡 발효 분획물은 우수한 항산화, 항고혈압 또는 미백활성을 갖는 특징이 있어 건강 기능성 식품, 화장품 및 의약품의 용도로 사용될 수 있는 효과가 있다.The process for producing the fermentation fraction of Omega-Kugi according to the present invention comprises the steps of: (a) preparing a fermentation product using omega-3; (b) obtaining a fermentation product having a molecular weight of 1 kDa or less from the fermentation product of step (a); And (c) fractionating the fermented product obtained in the step (b) by column chromatography. The fermented fraction of Omegigi produced by the above method has excellent antioxidant, antihypertensive or whitening activity Can be used for health functional foods, cosmetics and medicines.
도 1은 본 발명의 일실시예에서 제조한 오메기곡의 사진을 나타낸 것이다.
도 2는 본 발명의 일실시예에서 오메기곡을 이용한 발효물로부터 분획물을 제조하는 공정을 모식도로 나타낸 것이다.
도 3은 오메기곡을 이용한 발효물을 HPLC 컬럼 크로마토그래피로 분획화한 크로마토그램을 나타낸 것이다.
도 4는 본 발명의 오메기곡 발효물의 분획물에 대한 항산화 활성을 분석한 결과를 나타낸 것이다.
도 5는 본 발명의 오메기곡 발효물의 분획물에 대한 항고혈압 활성을 분석한 결과를 나타낸 것이다.
도 6은 본 발명의 오메기곡 발효물의 분획물에 대한 미백 활성을 분석한 결과를 나타낸 것이다.Fig. 1 shows a photograph of Omega Music produced in an embodiment of the present invention.
FIG. 2 is a schematic view showing a process for preparing a fraction from a fermented product using Omega-3 gypsum in one embodiment of the present invention.
FIG. 3 is a chromatogram showing the fractionation of the fermented product using Omega-Gog by HPLC column chromatography.
Fig. 4 shows the results of analysis of the antioxidative activity of the fractions of the Omega-3 fermented product of the present invention.
FIG. 5 shows the results of analysis of the antihypertensive activity of the fractions of the fermented product of Omega-3 according to the present invention.
Fig. 6 shows the results of analysis of the whitening activity of the fractions of the Omegi-type fermented product of the present invention.
본 발명은 항산화, 항고혈압 및 미백 활성이 우수한 기능성 식품, 화장품 및 의약품의 원료를 발굴하기 위해 연구하던 중, 오메기곡의 발효물 및 오메기곡 발효 분획물이 우수한 항산화, 항고혈압 및 미백 활성을 갖는다는 것을 확인하였다.The present invention relates to a fermented product of Omegigok and a fermented product of Omegi Goggles having excellent antioxidant, antihypertensive and whitening activity while investigating a raw material for functional foods, cosmetics and pharmaceuticals excellent in antioxidant, antihypertensive and whitening activity Respectively.
앞서 종래기술에서도 기재한 바와 같이, 오메기곡은 보통 술 제조에 사용되는 누룩으로 제주 지방에서는 토속주의 제조에 주로 사용되고 있다.As described in the prior art, Omegi is a yeast commonly used in the manufacture of alcoholic beverages, and is mainly used in the manufacture of local sake in Jeju Province.
본 발명에서는 이러한 오메기곡을 이용하여 발효물을 제조하였고, 특히 1kDa 이하의 분자량을 갖는 발효물이 항산화, 항고혈압 및 미백 활성이 우수하다는 것을 확인하였으며, 1kDa 이하의 분자량을 갖는 발효물을 컬럼크로마토그래피로 더욱 세분화시킨 분획물들에 대한 활성 분석을 통해 모든 분획물이 아닌 특정 분획물이 우수한 항산화, 항고혈압 및 미백 활성을 갖는다는 것을 규명하였다.In the present invention, a fermented product was prepared using this Omega Gage. Particularly, it was confirmed that a fermented product having a molecular weight of 1 kDa or less was excellent in antioxidant, antihypertensive and whitening activity. A fermented product having a molecular weight of 1 kDa or less was subjected to column chromatography The activity analysis of the fractions further fractionated showed that certain fractions, not all fractions, had excellent antioxidant, antihypertensive and whitening activity.
본 발명에서 사용한 상기 오메기곡은 시중에 판매되고 있는 오메기곡을 사용할 수 있도 있고, 또는 제조하여 사용할 수도 있는데, 오메기곡의 제조방법은, (a)통보리를 갈아서 세척한 후, 물에 8~12시간 침지시키는 단계; (b)물기를 제거하고 밀가루를 첨가하여 혼합하고 치대는 단계; (c)일정크기로 반죽물을 떼어 성형하는 단계; 및 (d)누룩틀 안에 성형한 반죽물을 넣고 발효시키는 단계를 포함한다.The omega music used in the present invention can be used or manufactured by using commercially available omega music. The production method of omega music is as follows: (a) Time immersing step; (b) remove the water and add flour to mix and stir; (c) peeling the kneaded product to a predetermined size and molding it; And (d) placing the kneaded product in a yeast mold and fermenting.
상기 (a) 단계에서 통보리를 물에 침지하는 단계를 위해 바람직하게 상기 통보리는 한번 갈은 통보리를 사용할 수 있으며, 물에 침지시키는 과정은 통보리와 물을 4:1~6:1의 부피비로 계산하여 수행할 수 있다.In the step (a), for example, in order to immerse the barley in water, the barley may be used in a manner that the barley can be used once, and the process of immersing in water may be performed in a volume ratio of 4: 1 to 6: 1 .
통보리를 갈아서 물에 침지하는 단계가 완료되면, 이후 반죽하는 과정을 수행하는데, 물에 침지시킨 통보리의 물기를 제거한 후, 밀가루를 첨가하여 혼합하고 치대는 단계를 수행한다. 이때 첨가하는 밀가루는 (a) 단계의 통보리 중량을 기준으로 밀가루 대 통보리를 1:15 ~1 :20 의 중량비로 사용하는 것이 바람직하다.After the step of grinding the sesame seeds and the step of immersing in water is completed, the process of kneading is carried out afterwards. After removing the moisture of the sesame seeds immersed in water, wheat flour is added and mixed, and the step is carried out. The wheat flour to be added at this time is preferably used in a weight ratio of 1:15 to 1:20 based on the weight of the sesame oil in step (a).
상기에서 본원발명에서 제공하는 밀가루 대 통보리 중량비의 범위를 벗어나서 사용하게 될 경우, 생성되는 반죽물의 점성이 너무 무르거나 너무 점성이 높아 제조되는 발효주의 품질을 저하시킬 수 있다. 즉 밀가루의 첨가량이 상기 범위 미만일 경우, 반죽물의 점성이 너무 낮아 누룩이 제대로 형성되지 못하는 문제가 있고, 밀가루의 첨가량이 상기 범위를 초과할 경우 반죽물의 점성이 높아져서 발효과정이 제대로 이루어지 않는 문제점이 발생할 수 있다.If the flour is used outside of the range of the flour to bread weight ratio provided by the present invention, the viscosity of the resulting batter may be too much or too high to lower the quality of the produced fermentation broth. That is, when the addition amount of the flour is less than the above range, there is a problem that the viscosity of the kneaded product is so low that the yeast is not properly formed. If the addition amount of the flour exceeds the above range, the viscosity of the kneaded product becomes high, Lt; / RTI >
또한, 상기 치대는 단계는 0.5~2 시간 동안 수행할 수 있다.Also, the step may be performed for 0.5 to 2 hours.
상기 과정이 완료되면 이후 반죽물을 성형하는 단계를 수행하는데, 반죽물은 일정 중량으로 일정 크기가 되도록 떼어낸 후, 둥글납작한 형태가 되도록 만들고 단단해지도록 압력을 가한다.After completion of the above process, a step of molding the kneaded product is performed. The kneaded product is peeled off to a predetermined size by a predetermined weight, and then the kneaded product is made to have a round flat shape and pressure is applied so as to be hardened.
본 발명의 일실시예에서는 어른 한 주먹 만한 크기로 반죽물을 떼어낸 후, 면보자기로 싸고 둥글납작한 형태가 되도록 만든 후, 밟아서 단단해 지도록 하는데, 이 과정을 거쳐 제조된 것이 애누룩이다.In an embodiment of the present invention, the kneaded product is taken out to an adult size and then wrapped with a cotton wrapper to form a round flat shape, which is then stepped on and tightened.
이후 누룩틀 안에 상기 과정으로 성형한 반죽물(즉, 애누룩)을 넣고 발효시키는 단계를 통해 오메기곡을 제조하여 사용하였다.Thereafter, omega curry was prepared and used in a step of putting the kneaded product (i.e., Ahnuraku) molded in the above-described process into the yeast mold and fermenting it.
또한 본 발명자들은 상기 오메기곡에 존재하는 우점종 미생물을 분석하였는데, 분석 결과, 아스퍼질러스 오리재(Aspergillus oryzae;균주명: F3-YG3), 자일라리아 아르부스큘라(Xylaria arbuscula; 균주명:F3-BG3), 뮤코 시넬로이드(Mucor circinelloides; 균주명: F3-B2), 사카로마이세스 세레비지애(Saccharomyces cerevisiae; 균주명: ReY3-1) 및 엔테로코코스 파에슘(Enterococcus faecium ; 균주명: L3-1)가 우점종하고 있음을 확인하였다.The present inventors have also analyzed microorganisms of dominant species present in the Omegi Valley. As a result of the analysis, Aspergillus ( Aspergillus oryzae) oryzae; Strain name: F3-YG3), character Ilaria are booth Circular (Xylaria arbuscula; Strain name: F3-BG3), myuko sinel Lloyd (Mucor circinelloides; Strain name: F3-B2), saccharose in my process three Levy jiae , Saccharomyces cerevisiae (strain name: ReY3-1) and Enterococcus faecium (strain name: L3-1) were dominant.
이에 본 발명자들은 이러한 오메기곡을 이용하여 항산화, 항고혈압 또는 미백활성을 갖는 오메기곡 발효 분획물의 제조공정을 확립하였는데, 구체적으로 상기 방법은, (a) 오메기곡을 이용하여 발효물을 제조하는 단계; (b) 상기 (a)단계의 발효물로부터 1kDa 이하의 분자량을 갖는 발효물을 수득하는 단계; 및 (c) 상기 (b) 단계에서 수득한 발효물을 컬럼 크로마토그래피를 수행하여 분획화하는 단계를 포함한다. Thus, the present inventors have established a process for producing Omegi's fermented fractions having antioxidant, antihypertensive or whitening activity using the Omega Curry. Specifically, the method comprises: (a) preparing a fermented product using omega curry; ; (b) obtaining a fermentation product having a molecular weight of 1 kDa or less from the fermentation product of step (a); And (c) fractionating the fermentation product obtained in the step (b) by performing column chromatography.
상기 (a)단계의 발효물은 오메기곡을 이용하여 20 ~ 45℃ 온도에서 7일~21일 동안 발효시켜 제조한다. 이때 상기 발효물은 오메기곡을 이용하여 곡물을 발효시키는 단계를 통해 제조할 수 있으며, 상기 발효물은 이에 제한되지는 않으나, 막걸리, 청주, 와인 또는 맥주일 수 있다. 본 발명의 일실시예에서는 막걸리를 제조하였다.The fermented product of step (a) is prepared by fermenting at 20 to 45 ° C for 7 days to 21 days using Omega Curve. At this time, the fermented product can be produced by fermenting cereals using omega curry, and the fermented product can be, for example, makgeolli, sake, wine or beer. In one embodiment of the present invention, makgeolli was prepared.
나아가 본 발명자들은 오메기곡 발효물에 대해 항산화, 항고혈압 및 미백활성이 더 현저하게 우수한 성분을 확인하기 위해 오메기곡 발효물을 분획화하고 각 분획물에 대한 효능 실험을 수행하였다.Further, in order to confirm that the fermented product of Omegigi has more superior antioxidant, antihypertensive and whitening activity, the present inventors fractionated the fermented product of Omegigi and conducted an efficacy test on each fraction.
먼저 오메기곡 발효물을 크기별 여과막을 이용하여 분획화한 후, 각 분획에 대해 활성 분석을 수행하였는데, 분석 결과 1kDa 이하의 분자량을 갖는 발효물이 1kDa을 초과하는 분자량을 갖는 발효물에 비해 더 우수한 항산화, 항고혈압 및 미백활성이 있다는 것을 알 수 있었다.First, the Omegigos fermented product was fractionated using a size-dependent filtration membrane, and the activity of each fraction was analyzed. As a result, it was found that the fermented product having a molecular weight of 1 kDa or less was superior to the fermented product having a molecular weight exceeding 1 kDa Antioxidant, antihypertensive and whitening activity.
따라서 본 발명자들은 오메기곡 발효물 중에서도 특정 분자량을 함유하는 발효물이 더 우수한 효능을 가지고 있다는 것을 알 수 있었고, 그 분자량이 1kDa 이하라는 것을 규명하였다.Therefore, the inventors of the present invention have found out that the fermented product having a specific molecular weight in the fermented product of Omegi has superior efficacy and its molecular weight is 1 kDa or less.
나아가 1kDa 이하의 분자량을 가지는 오메기곡 발효물을 다시 컬럼크로마토그래피를 수행하여 더욱 분획화한 다음, 각각의 분획물에 대한 활성 분석을 수행하였는데, 특이하게도 모든 분획물이 다 활성을 가지고 있는 것이 아니라 특정 분획물이 현저하게 우수한 활성을 가지고 있다는 것을 규명하였다.Furthermore, the Omegigok fermented product having a molecular weight of 1 kDa or less was further fractionated by further performing column chromatography, and then activity analysis was performed on each of the fractions. Specifically, not all fractions had multiple activities, Was found to have remarkably excellent activity.
구체적으로 오메기곡 발효물을 0.1% 포름산이 함유된 증류수 및 0.1% 포름산이 함유된 아세토니트릴의 혼합용매를 이용하여 농도구배로 분획화 하였는데, 0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 11.8~13.6 : 88.2~86.4로 하여 수득한 분획물이 다른 분획물에 비해 항고혈압 활성 및 미백 활성이 우수한 것으로 나타났다.Specifically, the Omegigok fermentation product was fractionated with a gradient of concentration using a mixed solvent of distilled water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid. Distilled water containing 0.1% formic acid: 0.1% formic acid The fraction obtained by mixing acetonitrile with a solvent concentration gradient of 11.8 ~ 13.6: 88.2 ~ 86.4 showed higher antihypertensive activity and whitening activity than the other fractions.
또한, 0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 16.4~18.0 : 83.6~82.0으로 하여 수득한 분획물은 다른 분획물에 비해 항산화 활성이 월등히 우수한 것으로 나타났다.Further, the fraction obtained by mixing solvent concentration gradient 16.4-18.0: 83.6-82.0 of distilled water containing 0.1% formic acid: acetonitrile containing 0.1% formic acid showed significantly higher antioxidative activity than the other fractions.
그러므로 본 발명은 오메기곡 발효물 또는 오메기곡 발효 분획물을 유효성분으로 포함하는 항산화 또는 항고혈압 식품 조성물을 제공할 수 있다.Therefore, the present invention can provide an antioxidant or antihypertensive food composition comprising an Omega-3 fermented product or an Omega-3 fermented product as an active ingredient.
본 발명에서 제공하는 상기 식품 조성물은 과도한 활성산소에 의해 유발되거나 또는 활성산소에 의해 매개되거나 또는 결과적으로 과도한 활성산소를 발생시키는 다양한 질환을 예방, 치료 또는 개선시키기 위해 사용될 수 있고, 또한 고혈압의 예방, 치료 또는 개선을 위해 사용될 수 있다. The food composition provided by the present invention can be used to prevent, treat or ameliorate various diseases caused by excessive active oxygen or by active oxygen or consequently excessive active oxygen, , ≪ / RTI >
상기 활성산소에 의해 유발될 수 있는 질환으로는 이에 제한되지는 않으나, 동맥경화증, 루게릭병, 파킨슨병, 알츠하이머, 근위축색경화증 및 헌팅톤병을 포함하는 퇴행성 신경질환, 심근경색, 협심증, 관상동맥질환, 허혈성 심장질환을 포함하는 심혈관 질환, 뇌졸중을 포함하는 허혈성 뇌질환, 당뇨병, 위염 및 위암을 포함하는 소화기계 질환, 노화, 암, 백혈병, 노화, 류마티스 관절염, 간염, 아토피성 피부염 등 다양한 질환을 포함할 수 있다.Diseases that may be caused by the active oxygen include, but are not limited to, degenerative neurological diseases including arteriosclerosis, Lou Gehrig's disease, Parkinson's disease, Alzheimer's, proximal axillary sclerosis and Huntington's disease, myocardial infarction, angina pectoris, coronary artery disease , Cardiovascular diseases including ischemic heart diseases, ischemic brain diseases including stroke, diabetes, gastrointestinal diseases including gastritis and gastric cancer, aging, cancer, leukemia, aging, rheumatoid arthritis, hepatitis and atopic dermatitis .
본 발명에서 제공하는 식품 조성물은 식품의 형태로 제조되어 섭취할 수 있으며, 상기 식품에 포함되는 상기 식품 조성물의 함량은 특별히 이에 제한되지 않으나, 식품의 총 중량에 대하여 상기 조성물은 0.001 내지 10 중량%, 보다 바람직하게는 0.1 내지 1 중량%로 포함될 수 있다. 식품이 음료인 경우에는 100㎖를 기준으로 1 내지 10g, 바람직하게는 2 내지 7g의 비율로 포함될 수 있다. 또한, 상기 식품은 식품 조성물로서 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분 을 포함할 수 있다. 예들 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레 이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬 (Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. 또한, 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 첨가할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용된다.The content of the food composition contained in the food is not particularly limited, but it is preferably 0.001 to 10% by weight based on the total weight of the food, By weight, more preferably 0.1 to 1% by weight. When the food is a beverage, it may be contained in a proportion of 1 to 10 g, preferably 2 to 7 g based on 100 ml. In addition, the food may contain additional ingredients which are commonly used as food compositions and which can improve odor, taste, visual appearance and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid and the like. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn) and copper (Cu) It may also include amino acids such as lysine, tryptophan, cysteine, valine, and the like. In addition, it is also possible to use antiseptics (such as potassium sorbate, sodium benzoate, salicylic acid, and sodium dehydroacetate), disinfectants (such as bleaching powder and highly bleached white powder, sodium hypochlorite), antioxidants (butylhydroxyanilide (BHA), butylhydroxytoluene BHT), etc.), coloring agents (such as tar pigments), coloring agents (such as sodium nitrite and sodium acetic acid), bleaching agents (sodium sulfite), seasoning (such as MSG sodium glutamate), sweeteners (such as hypoglycemia, , Food additives such as flavorings (vanillin, lactones, etc.), swelling agents (alum, potassium hydrogen D-tartrate), emulsifiers, emulsifiers, thickeners, encapsulating agents, gum bases, foam inhibitors, ) Can be added. The additives are selected according to the type of food and used in an appropriate amount.
또한 본 발명은 오메기곡 발효물 또는 오메기곡 발효 분획물을 유효성분으로 포함하는 항산화 또는 피부미백용 화장료 조성물을 제공할 수 있다.The present invention also provides a cosmetic composition for antioxidant or skin whitening comprising an Omega-3 fermented product or an Omega-3 fermented fraction as an active ingredient.
바람직하게 본 발명에 따른 상기 화장료 조성물에 함유되는 상기 분획물은 1kDa 이하의 분자량을 갖는 오메기곡 발효물을 컬럼 크로마토그래피를 수행하여 수득한 것으로, 0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 11.8~13.6 : 88.2~86.4로 하여 수득한 분획물은 미백활성이 우수하며, 0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 16.4~18.0 : 83.6~82.0으로 하여 수득한 분획물은 항산화 활성이 우수한 특징이 있다. 이러한 결과는 본 발명의 실시예에 의한 실험을 통해 확인한 결과이다. Preferably, the fraction contained in the cosmetic composition according to the present invention is obtained by performing column chromatography on Omegigok's fermented product having a molecular weight of not more than 1 kDa, and is characterized in that distilled water containing 0.1% formic acid: 0.1% The fraction obtained by mixing acetonitrile with a mixed solvent concentration gradient of 11.8 to 13.6: 88.2 to 86.4 had a whitening activity and a mixed solvent concentration gradient of distilled water containing 0.1% formic acid: acetonitrile containing 0.1% formic acid was 16.4 To 18.0: 83.6 to 82.0. The obtained fraction has an excellent antioxidative activity. These results are the results obtained through experiments according to the embodiments of the present invention.
본 발명의 화장료 조성물에 포함되는 성분은 유효성분으로서 오메기곡 발효물 또는 오메기곡 발효 분획물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다. The components contained in the cosmetic composition of the present invention may contain, as an active ingredient, components commonly used in cosmetic compositions in addition to the omega-3 fermented product or the omega-3 fermented fraction, and examples thereof include antioxidants, stabilizers, dissolving agents, vitamins, pigments And customary adjuvants such as perfumes, and carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 본 발명의 화장료 조성물은 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다. The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used in the form of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, the cosmetic composition of the present invention can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. 본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다. 본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다. 본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다. 본 발명의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다. When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component . When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters. In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used. When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether. When the formulation of the present invention is a surfactant-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether Alkylamido betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are for further illustrating the present invention, and the scope of the present invention is not limited to these examples.
<< 실시예Example 1> 1>
오메기곡Omegigok 제조 Produce
본 발명자들은 하기와 같은 방법으로 오메기곡, 즉 오메기 누룩을 제조하였다. 오메기곡 제조를 위해 먼저 제주지방의 통보리(두줄보리) 18.04L를 한번 갈아서 씻은 후, 깨끗한 새 물(3.6L)에 10시간 동안 담가두었다. 이후 통보리가 물러진 상태가 되면 물기를 빼고 밀가루 900g을 첨가하여 혼합한 후, 치대었다. 이후 한 주먹 크기로 떼어 면보자기로 싸고 둥글납작하게 단단하게 밟은 다음, 항아래 안에 볏짚을 잘게 썰어 깔고 그 위에 애누룩(상기 과정에서 둥글납작하게 만든 애누룩)놓았고, 이때 누룩 사이에는 볏짚을 끼워두었다. 이후 맨 위에는 볏짚과 종이를 씌워 띄워두었고 3일 간격으로 총 21 일 동안 볏짚을 갈아주고 뒤집어 주시면 오메기곡을 제조하였다. 제조된 본 발명의 오메기곡 사진은 도 1에 나타내었다. The inventors of the present invention produced omega nuggets, namely, omegi nuggets by the following method. For the production of Omegigi, 18.04L of Tongbori of Jeju province was first grinded and washed, then immersed in clean fresh water (3.6L) for 10 hours. Thereafter, wheat flour was added to 900 g of wheat flour, followed by mixing. Then, when it was separated by a fist size, it was wrapped with a wrapping cloth and firmly pressed with a round flat. Then, the rice straw was sliced into pieces under the bag, and then Anunouk (a flattened flattened product in the above process) was put thereon. I have. After that, rice straw and paper were put on the top, and Omegigi was prepared by changing the rice straw for a total of 21 days at intervals of 3 days. The produced Omega music image of the present invention is shown in Fig.
<< 실시예Example 2> 2>
본 발명의 The 오메기곡에Omegigoto 함유된 균주의 분리 및 동정 Isolation and Identification of Containing Strain
상기 실시예 1의 방법으로 제조한 본 발명의 오메기곡에 존재하고 있는 우점종 미생물을 분리 및 동정하였다. 미생물 확인을 위해 상기 실시예 1에서 제조한 본 발명의 오메기곡을 균질화하여 10배 희석법을 이용하여 희석한 후, 식품공전에 의한 표준평판 배지를 이용하여 균수를 측정하였다. 균수 측정에 사용된 표준한천 플레이트 위에 다수의 균 집락을 형성한 플레이트 (plate)를 선정하고, 시료 당 집락을 이루는 우점종 미생물을 순수분리 하였고, 순수 분리한 균주의 DNA를 추출(99℃, 10min) 후 ITS1(5’-TCCGTAGGTGAACCTGCGG-3’), ITS4(5’-TCCTCCGCTTAT TGATATGC-3’) 프라이머를 사용하여 PCR 하였다. 증폭된 DNA를 정제 후, ABI PRISM® BigDyeTM Terminator Cycle Sequencing Kit를 사용하고, PCR과 동일한 프라이머를 이용하여 16S rDNA 염기서열을 시퀀싱(ABI PRISM® 3730XL DNA Analyzer, Applied Biosystems, Foster City, CA, USA)하였다. 분석된 염기서열을 BLAST(http://www.ncbi.nlm.nih.gov) 프로그램을 이용하여 미생물 동정을 수행하였다. 또한, 본 발명에 따른 오메기곡에 함유된 우점종의 미생물들의 종류와 점유율 분석을 위해 메타 제놈(metagenome) 분석을 수행하였는데, 실시예 1에서 제조한 오메기곡 누룩 샘플의 DNA/RNA를 추출하여 quality control(QC)을 확인한 후 통과된 샘플에 대해 라이브러리 구축을 진행하였다. 시퀀싱 라이브러리는 5‘ 및 3’어댑터 결합에 따른 DNA 또는 cDNA 샘플의 무작위 조각화에 의해 준비하거나 라이브러리 준비과정의 효율성을 향상시키는 단일 스텝으로 fragmentation 과 ligation 반응을 결합한 tagmentation으로 진행하여 어댑터와 연결된 조각들을 PCR 증폭하고 gel 정제를 수행하였다. The microorganisms of the dominant species present in the Omega Valley of the present invention prepared by the method of Example 1 were isolated and identified. For identification of the microorganism, the omega bacterium of the present invention prepared in Example 1 was homogenized and diluted using a 10-fold dilution method, and then the number of bacteria was measured using a standard plate medium by food revolution. Plates on which a number of bacterial colonies were formed were selected on a standard agar plate used for bacterial counting, and the dominant microorganisms forming the colonies per sample were purified, and DNA of the purely isolated strains was extracted (99 ° C, 10 min) PCR was performed using primers ITS1 (5'-TCCGTAGGTGAACCTGCGG-3 ') and ITS4 (5'-TCCTCCGCTTAT TGATATGC-3'). After digesting the amplified DNA, 16S rDNA sequence was sequenced (ABI PRISM® 3730XL DNA Analyzer, Applied Biosystems, Foster City, CA, USA) using the ABI PRISM® BigDye ™ Terminator Cycle Sequencing Kit, Respectively. The analyzed nucleotide sequence was subjected to microbiological identification using BLAST (http://www.ncbi.nlm.nih.gov) program. In addition, metagenome analysis was performed to analyze the types and share of the dominant species contained in the Omegigi according to the present invention. The DNA / RNA of the Omegigon's yeast sample prepared in Example 1 was extracted and subjected to quality control (QC), and library construction was performed on the passed samples. Sequencing libraries can be prepared by random fragmentation of DNA or cDNA samples according to 5 'and 3' adapter binding, or by tagging with a combination of fragmentation and ligation reactions in a single step that enhances the efficiency of library preparation, Amplified and gel purified.
클러스터 생성을 위해 라이브러리 결합체와 상보적인 표면 결합 올리고체 각 단편은 브릿지 증폭을 통해 뚜렷한 클론 클러스터 생성을 완료하고 시퀀싱할 준비가 된 template을 만든다. Illumina SBS 기술인 가역 터미네이터 기반의 방법을 사용하여 DNA template 가닥을 만들고 4개의 가역적인 terminator-bond dNTP가 각 시퀀싱 주기 동안 존재하여 오류를 대폭 감소시켰다. 매우 정확한 base-by-base 시퀀싱 분석결과 데이터는 raw data로 변환시켜 metagenome 분석을 수행하였다. 오메기곡 누룩에 존재하는 확인된 우점종 미생물의 결과를 하기 표 1에 나타내었다. For clustering, each piece of surface-bound oligosaccharide complementary to the library assembly completes the distinct clone clustering through bridge amplification and creates a template ready for sequencing. Using Illumina SBS technology, a reversible terminator-based method was used to create DNA template strands and four reversible terminator-bond dNTPs were present during each sequencing cycle, greatly reducing errors. Based on highly accurate base-by-base sequencing analysis, data were converted to raw data and metagenome analysis was performed. The results of the identified dominant species microorganisms present in Omegigono leu are shown in Table 1 below.
분석 결과, 상기 표 1에 나타낸 바와 같이 본 발명의 오메기곡에는 5가지 미생물이 우점종균으로 존재하고 있는 것으로 나타났으며, 구체적으로 Rhizopus oryzae가 80.7%의 점유율을 보였고, 그 뒤로 Aspergillus oryzae 17.9%, Mucor circinelloides 1.1%의 점유율을 보였고, Saccharomyces cerevisiae 및 Enterococcus faecium이 각각 0.2% 및 0.1%의 점유율을 보였다.As a result of the analysis, as shown in Table 1, five microorganisms were present as dominant bacteria in the Omega Gram of the present invention. Specifically, Rhizopus oryzae occupied 80.7%, followed by Aspergillus oryzae 17.9% Mucor circinelloides had a share of 1.1%, Saccharomyces cerevisiae and Enterococcus faecium had 0.2% and 0.1%, respectively.
<< 실시예Example 3> 3>
본 발명의 The 오메기곡을Omegigok 이용한 Used 발효물Fermentation product 제조 Produce
본 발명자들은 상기 실시예 1에서 제조한 본 발명의 오메기곡을 이용하여 발효물의 한 종류로서 막걸리를 제조하였다. 막걸리의 제조를 위해 실시예 1에서 제조한 오메기 누룩을 이용하였는데, 먼저 쌀 144g을 세척하고 3시간 침지하여 물기를 빼고 증자한 후 오메기곡 50g과 물 288ml을 첨가하여 밑술을 제조하였다. 이후 25℃에서 2일간 발효시킨 다음, 원료곡물인 쌀 288g을 증자(고두밥)하여 물 578ml과 첨가하고 덧술을 제조한 후 25℃에서 7일간 발효시켜 오메기곡을 이용한 발효물(막걸리)를 제조하였다.The present inventors have made makgeolli as a kind of fermented product using the omega music of the present invention prepared in Example 1 above. First, 144 g of rice was washed and immersed for 3 hours to remove water, and then 50 g of Omega Giga and 288 ml of water were added to prepare makgeolli. Then, after fermentation at 25 ° C for 2 days, 288 g of rice grains as a raw material grain were added (rice cake) and 578 ml of water was added, and the paste was prepared and fermented at 25 ° C for 7 days to prepare a fermented product (rice wine) .
<< 실시예Example 4> 4>
본 발명의 The 오메기곡을Omegigok 이용한 Used 발효물로부터From the fermentation product 항산화, 항고혈압 및 Antioxidant, anti-hypertensive and 미백활성이Whitening activity 우수한 Excellent 분획물의Fraction 제조 Produce
실시예 3에서 제조한 오메기곡의 발효물로부터 항산화, 항고혈압 및 미백 활성이 우수한 분획물을 수득하기 위해 다음과 같은 실험을 수행하였다. 먼저 1 kDa ?터(Ultracel® 1 kDa ultrafilteration dics, merk, USA)를 장착한 ultrafiltration cell(Amicon 8200 Pmax 75 psi, 5.3 Kg/cm2, merk, USA)을 이용하여 본 발명의 오메기곡의 발효물을 여과시켰다. 여과한 시료를 분획 수집기(fraction collector (G1364C 1260 FC-AS, Agilent, USA))가 연결된 HPLC(1260 HPLC system, Agilent, USA)를 이용하여 분획물을 수득하였는데, 이때 컬럼은 Zorbax RX-SIL(9.4mm x 250mm x 5 ㎛, Agilent, USA)를 이용하였고, 컬럼 오분의 온도는 30℃로 설정하였고, 50㎕을 주입하였다. 이동상은 0.1% 포름산이 용해된 물(A)과 0.1% 포름산이 용해된 아세토니트릴 용매(B)을 이용하였으며, 농도구배 조건은 B(90%)에서 시작하여 0.1분간 유지한 후, 14분에 B(80%), 16분에 B(40%)로 감소시킨 뒤 18분에 다시 B(90%)로 2분간 유지하였다. 유속은 1.0 ml/min로 흘려주며 195 nm에서 흡광도를 측정하였고 20분간 분리하였다. 분획물은 컬럼 용출시간이 2.5-5 min(구간 1), 5-9 min(구간 2), 9-11.2 min(구간 3), 11.2-15.5 min(구간 4), 15.5-20 min(구간 5)로 총 5구간을 나누어 수집하였고, speed-vac(Labconco, USA)으로 용매를 제거하였다. 오메기곡 발효물로부터 상기 각 분획물을 수득하는 공정의 모식도는 도 2에 나타내었고, HPLC 컬럼 크로마토그래피로 분획화된 분헉 결과는 도 3에 나타내었다. The following experiment was carried out to obtain a fraction having excellent antioxidant, antihypertensive and whitening activity from the fermented product of Omegigi produced in Example 3. First, the fermentation of the Omegigi of the present invention was performed using an ultrafiltration cell (Amicon 8200 Pmax 75 psi, 5.3 Kg / cm 2, merk, USA) equipped with a 1 kDa column (
또한, 상기 실험에서 각 구간별 분획물의 수득을 위해 컬럼 크로마토그래피 수행 시, 사용된 용매 비율은 하기 표에 기재된 바와 같다. Further, in the above experiment, when performing column chromatography for obtaining fractions for each section, the solvent ratio used is as shown in the following table.
상기에서 수득한 각 분획물에 대해서는 항산화 활성, 항고혈압 활성, 미백 활성 평가를 수행하였다. 항산화 활성 분석은 각 분획물 시료(50mg/ml)를 DMSO에 녹인 후, DPPH(2,2-diphenyl-1-picrylhydrazyl) 분석을 통해 DPPH 라디칼 소거활성을 측정하였는데, 각 분획물을 원심분리하고 상등액을 3차 증류수에 4배 희석한 다음, 시료(분획물) 0.2 ml에 에탄올로서 1.5×10-4M 농도가 되게 한 DPPH(1,1- diphenyl- 2 - picrylhydrazyl)용액 0.8 ml씩을 보텍스(vortex)로 균일하게 혼합한 다음, 실온에서 30분간 방치한 후 525nm에서 흡광도(O.D.)를 측정하였다. 또한, DPPH 라디칼 소거활성은 아래와 같은 식으로 계산하여 백분율(%)로 표시하였다.Antioxidant activity, antihypertensive activity and whitening activity of each of the fractions obtained above were evaluated. DPPH radical scavenging activity was measured by DPPH (2,2-diphenyl-1-picrylhydrazyl) analysis after each fraction sample (50 mg / ml) was dissolved in DMSO. Each fraction was centrifuged and the supernatant was dissolved in 3 0.8 ml of a DPPH (1,1-diphenyl-2-picrylhydrazyl) solution having a concentration of 1.5 × 10 -4 M as ethanol was added to 0.2 ml of a sample (fraction) in a vortex, After incubation at room temperature for 30 minutes, the absorbance (OD) was measured at 525 nm. The DPPH radical scavenging activity was expressed as a percentage (%) by the following formula.
DPPH 라디칼 소거활성(%) = DPPH radical scavenging activity (%) =
[1-(음성 대조구(control) 흡광도 ÷ 실험구 흡광도)] × 100[1- (negative control (control) absorbance / experiment absorbance)] x 100
또한, 항고혈압 측정은, 각 분획물 시료(50mg/ml)를 DMSO에 녹인 후, angiotensin converting enzyme (ACE) 활성 저해능을 평가하는데, ACE 활성 저해 정도를 측정하기 위하여 porcin kidney에서 분리한 ACE와 그 기질로 0.3% Hippuryl-L-Histidyl-L-Leucine (HHL)을 사용하였다. ACE가 기질인 HHL과 반응하여 hippuric acid를 생성하게 되는데 시료 처리 시 생성되는 hippuric acid의 정도를 control 대비 저해 정도로 표시하였고 ACE inhibitor의 역할을 할 수 있는 시료 선별을 위하여 우선적으로 50 mg/ml의 농도에서 ACE inhibition 정도를 측정하여 항고혈압 효능을 확인하였다.In order to measure the antihypertensive effect, angiotensin converting enzyme (ACE) inhibition activity was measured by dissolving each fraction sample (50 mg / ml) in DMSO. To measure the degree of inhibition of ACE activity, ACEs isolated from porcin kidney and its substrate And 0.3% Hippuryl-L-Histidyl-L-Leucine (HHL) was used. ACE reacts with substrate HHL to produce hippuric acid. The degree of hippuric acid produced during the sample treatment is indicated as inhibition level compared to control. For the screening of ACE inhibitor, 50 mg / ml And the antihypertensive effect was confirmed by measuring the degree of ACE inhibition.
미백활성 측정은, 각 분획물 시료(50 mg/ml)를 DMSO에 녹인 후, tyrosinase 활성 저해능을 평가하였는데, 이를 위하여 mushroom tyrosinase과 tysorine을 기질로 사용하여 37도에서 30분에서 60분까지 반응시키면서 흡광도를 kinetic으로 측정하였다. 이 시간동안 생성된 DOPA (dihydroxyphenylalaine)은 510 nm 흡광도 측정을 통하여 분획물 시료의 tyrosinase 효소 활성 억제능을 측정하였다. 아래의 계산식에 따라 tyrosinase inhibitor 역할, 즉 미백 효능을 가진 시료 선별을 위하여 25, 50 mg/ml의 농도에서 tyrosinase inhibition 정도를 측정하여 미백 효능을 확인하였다.The activity of each fraction (50 mg / ml) was dissolved in DMSO, and the inhibitory activity of tyrosinase activity was evaluated. For this purpose, mushroom tyrosinase and tysorine were used as substrates and incubated at 37 ° C for 30 minutes to 60 minutes. Was measured as kinetic. DOPA (dihydroxyphenylalaine) produced during this time was measured by measuring absorbance at 510 nm and the inhibitory activity of tyrosinase enzyme activity of the fractions was measured. The inhibitory effect of tyrosinase, ie, tyrosinase inhibition at 25 and 50 mg / ml, was tested for whitening efficacy.
Tyrosinase 저해 효능 (%) = Tyrosinase Inhibitory Activity (%) =
[(slope of EC slope of S) / slope of EC] × 100[(slope of EC slope of S) / slope of EC] x 100
* slope : (흡광도2-흡광도1)/(시간2-시간1)* slope: (absorbance 2 - absorbance 1) / (time 2 - time 1)
* EC : enzyme control, 음성대조군* EC: enzyme control, negative control
* S : sample, 분획물 시료 첨가군* S: sample, fraction added sample
분석 결과, 오메기곡 발효물로부터 분획화하여 수득한 분획물 중에서 항산화 활성을 분획물 3(Fraction 3)이 다른 분획물에 비해 월등히 우수한 것으로 나타났고(도 4 참조), 항고혈압 활성과 미백활성은 분획물 1(Fraction 1)이 다른 분획물에 비해 월등히 우수한 것으로 나타났다(도 5 및 조 6 참조). 또한 본 발명의 오메기곡 발효분획물이 나타내는 특정 분획물들의 항산화 활성, 항고혈압 활성 및 미백활성은 종래 누룩 또는 누룩을 이용한 발효물이 나타내는 효과에 비해서도 월등히 우수한 효과를 나타낸다는 것을 알 수 있었다.As a result of the analysis, it was found that the antioxidative activity of the fractions obtained by fractionation from the Omegi type fermentation product was much better than that of the other fractions of Fraction 3 (see FIG. 4), and the antihypertensive activity and whitening activity were in the
따라서 본 발명자들은 오메기곡 발효물을 이용하여 다양한 기능성 제품을 제조할 경우, 항산화 활성이 우수한 제품을 위해서는 분획물 3을 사용하는 것이 최대의 효과를 도출할 수 있음을 알 수 있었고, 항고혈압 활성과 미백활성을 위해서는 분획물 1을 사용하는 것이 가장 좋다는 것을 알 수 있었으며, 본 발명의 분획물 1 및 3을 사용하여 제조한 제품은 종래 항산화, 항고혈압 또는 미백활성을 갖는 제품을 충분히 대체할 수 있다.Therefore, the inventors of the present invention found that the use of fraction 3 for the production of various functional products using the fermented product of Omegigi for antioxidant activity has the greatest effect, and the antihypertensive activity and whitening It was found that
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.
Claims (9)
(b) 상기 (a)단계의 발효물로부터 1kDa 이하의 분자량을 갖는 발효물을 수득하는 단계; 및
(c) 상기 (b) 단계에서 수득한 발효물을 0.1% 포름산이 함유된 증류수 및 0.1% 포름산이 함유된 아세토니트릴의 혼합용매를 이용하여 농도구배로 컬럼 크로마토그래피를 수행하여 분획화하는 단계를 포함하되,
0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 11.8~13.6 : 88.2~86.4로 하여 항고혈압 및 미백 활성을 갖는 분획물을 수득하는 것을 특징으로 하는,
항고혈압 및 미백 활성을 갖는 오메기곡 발효 분획물의 제조방법.(a) preparing a fermented product by using Omega Goku;
(b) obtaining a fermentation product having a molecular weight of 1 kDa or less from the fermentation product of step (a); And
(c) fractionating the fermentation product obtained in step (b) by concentration gradient using a mixed solvent of distilled water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid Including,
Characterized in that a fraction having an antihypertensive and whitening activity is obtained by setting a mixed solvent concentration gradient of distilled water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid to 11.8 to 13.6: 88.2 to 86.4.
A method for producing fermentation broth of Omegi Valley having antihypertensive and whitening activity.
상기 (a)단계의 발효물은 오메기곡을 이용하여 20 ~ 45℃ 온도에서 7일~21일 동안 발효시켜 제조한 발효물인 것을 특징으로 하는, 항고혈압 및 미백 활성을 갖는 오메기곡 발효 분획물의 제조방법.The method according to claim 1,
The fermentation product of step (a) is a fermentation product produced by fermenting the fermented product at 20 to 45 ° C for 7 to 21 days using the Omegi crab. Way.
(b) 상기 (a)단계의 발효물로부터 1kDa 이하의 분자량을 갖는 발효물을 수득하는 단계; 및
(c) 상기 (b) 단계에서 수득한 발효물을 0.1% 포름산이 함유된 증류수 및 0.1% 포름산이 함유된 아세토니트릴의 혼합용매를 이용하여 농도구배로 컬럼 크로마토그래피를 수행하여 분획화하는 단계를 포함하되,
0.1% 포름산이 함유된 증류수 : 0.1% 포름산이 함유된 아세토니트릴의 혼합용매 농도구배를 16.4~18.0 : 83.6~82.0으로 하여 항산화 활성을 갖는 분획물을 수득하는 것을 특징으로 하는,
항산화 활성을 갖는 오메기곡 발효 분획물의 제조방법.(a) preparing a fermented product by using Omega Goku;
(b) obtaining a fermentation product having a molecular weight of 1 kDa or less from the fermentation product of step (a); And
(c) fractionating the fermentation product obtained in step (b) by concentration gradient using a mixed solvent of distilled water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid Including,
Characterized in that a fraction having an antioxidative activity is obtained by setting a mixed solvent concentration gradient of distilled water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid as 16.4 to 18.0: 83.6 to 82.0.
A method for producing fermentation broth of Omegi Valley having antioxidant activity.
상기 (a)단계의 발효물은 오메기곡을 이용하여 20 ~ 45℃ 온도에서 7일~21일 동안 발효시켜 제조한 발효물인 것을 특징으로 하는, 항산화 활성을 갖는 오메기곡 발효 분획물의 제조방법.The method of claim 3,
Wherein the fermented product of step (a) is a fermented product produced by fermenting the fermented product at 20 to 45 ° C. for 7 to 21 days using Omega Gouge.
항고혈압 식품 조성물.The fractions obtained by subjecting the Omegigok fermented product having a molecular weight of 1 kDa or less to column chromatography were 0.1% formic acid-containing distilled water: 0.1% formic acid-containing acetone Nitrile is in the range of 11.8 to 13.6: 88.2 to 86.4.
Antihypertensive food composition.
미백용 식품 조성물.The fractions obtained by subjecting the Omegigok fermented product having a molecular weight of 1 kDa or less to column chromatography were 0.1% formic acid-containing distilled water: 0.1% formic acid-containing acetone Nitrile is in the range of 11.8 to 13.6: 88.2 to 86.4.
A whitening food composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170085293A KR101988255B1 (en) | 2017-07-05 | 2017-07-05 | Fraction of fermented product using omeginuruk having antioxidative, antihypertensive and whitening activity and method of preparing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170085293A KR101988255B1 (en) | 2017-07-05 | 2017-07-05 | Fraction of fermented product using omeginuruk having antioxidative, antihypertensive and whitening activity and method of preparing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190004918A KR20190004918A (en) | 2019-01-15 |
KR101988255B1 true KR101988255B1 (en) | 2019-06-12 |
Family
ID=65030270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170085293A KR101988255B1 (en) | 2017-07-05 | 2017-07-05 | Fraction of fermented product using omeginuruk having antioxidative, antihypertensive and whitening activity and method of preparing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101988255B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240060021A (en) | 2022-10-28 | 2024-05-08 | 중앙대학교 산학협력단 | Method of obtaining bioactive peptides derived from Korean native cattle with antihypertensive and antioxidant activity |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101571517B1 (en) * | 2015-04-13 | 2015-11-24 | 주식회사 코씨드바이오팜 | Antiaging cosmetics containing the extract of Saururus chinensis (Lour.) Baill. with improved anti-wrinkle and antioxidant activity by Jeju Shindari fermentation method |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101134890B1 (en) * | 2009-08-10 | 2012-04-13 | (주)아모레퍼시픽 | Composition containing Concentrated Makgeolli for antioxidation and whitening effect |
KR20120071932A (en) | 2010-12-23 | 2012-07-03 | 순창군 | Lactic acid fermented solution of wild plant with enhanced antioxidative and antihypertensive activity |
KR101531996B1 (en) | 2014-10-29 | 2015-06-26 | 재단법인 금산국제인삼약초연구소 | Cosmetics comprising fermented materials for skin whitening |
-
2017
- 2017-07-05 KR KR1020170085293A patent/KR101988255B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101571517B1 (en) * | 2015-04-13 | 2015-11-24 | 주식회사 코씨드바이오팜 | Antiaging cosmetics containing the extract of Saururus chinensis (Lour.) Baill. with improved anti-wrinkle and antioxidant activity by Jeju Shindari fermentation method |
Non-Patent Citations (1)
Title |
---|
‘제주 유래 쉰다리 및 오메기술 공법을 응용한 제주산 특용작물의 화장품 소재 사업화’에 대한 연구과제보고서. ㈜코씨드바이오팜. 농림축산식품부 (2015.01.19.)* |
Also Published As
Publication number | Publication date |
---|---|
KR20190004918A (en) | 2019-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee et al. | Antioxidant activity and γ-aminobutyric acid (GABA) content in sea tangle fermented by Lactobacillus brevis BJ20 isolated from traditional fermented foods | |
JP4163631B2 (en) | Fermentation composition of spicy varieties of chili pepper and its use | |
EP2484355B1 (en) | Laminin-332 production stimulating composition | |
KR101768921B1 (en) | Pediococcus acidilactici SRCM 102024 starter strain for producing fermented grain with improved antimicrobial activity and uses thereof | |
KR101429161B1 (en) | Cosmetic composition including uncooked rice wine ane the preparion method tehreof | |
CN109996885A (en) | Exocellular polysaccharide of lactic acid bacteria and application thereof | |
JP2015061517A (en) | Processed brown rice, fermented food, and manufacturing method of processed brown rice | |
CN101965958A (en) | Production technology of preserved beancurd juice | |
KR102314654B1 (en) | Composition for skin wrinkle improvement or anti-inflammation comprising extract of fermented Centella asiatica with improved antioxidant activity as effective component | |
CN106360666A (en) | Astaxanthin-containing anti-oxidation nutritional health product | |
KR101988255B1 (en) | Fraction of fermented product using omeginuruk having antioxidative, antihypertensive and whitening activity and method of preparing the same | |
JP5965875B2 (en) | Method for producing D-amino acid | |
JP5888763B2 (en) | Fermented buckwheat extract | |
KR20180119548A (en) | Omeginuruk for manufacturing fermented liquor and fermented liquor having anti-oxidative activity prepared by using thereof | |
EP2127647A1 (en) | Composition for inhibiting muscle damage | |
JPH06199679A (en) | Tyrosinase inhibitor | |
KR100849678B1 (en) | Extracts of soy hypocotyl with effects on skin whitening and composition comprising the same | |
JP2006282648A (en) | Food composition for cosmetic purpose | |
Chioza et al. | A comparative study on chemical composition and pharmacological effects of Paecilomyces hepiali and wild Ophiocordyceps sinensis | |
KR20220048717A (en) | A natural flavor composition comprising Debaryomyces with excellent 4-vinylguaiacol productivity | |
KR101881419B1 (en) | Manufacturing method for extracts based on leegangju base material, extracts manufactured by thereof method and cosmetic composition containing thereof extracts | |
KR20200031055A (en) | Cosmetic composition for anti-wrinkle and enhancing elasticity comprising fermented extract of Phragmites Communis | |
EP2484356A1 (en) | Oral composition for reducing wrinkle formation | |
JP2012140618A (en) | Process for producing antioxidant | |
JP2005176776A (en) | Method for producing vinegar and refreshing drink using washed water of rice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |